Kathryn joined De Novo Ventures in September 2005. Prior to De Novo, Kathryn worked for Merck & Co., Inc from 1997-2003 in the US, Europe and Asia. Her experience includes process engineering, equipment and automation design, procurement, process validation, plant construction and operations. At Merck, she played a key role in the design, construction, commissioning and start up of a $400 MM grassroots bulk chemical manufacturing facility in Singapore, Merck’s first new site in 40 years. On this project, Kathryn led the design of $30 MM of large scale automated manufacturing equipment from inception through start-up production, while stationed in England and Singapore for five years. In this role, she oversaw several multinational cross-functional teams to expedite project issues, resulting in the successful on-time start-up of the Singapore facility.
In addition, Kathryn worked at Genentech in strategic planning and operations strategy. Working closely with Marketing, Finance, R&D and Manufacturing, she performed capacity planning for E.coli product pipelines and identified potential spin-out candidates in light of operational, regulatory and investment risks.
Kathryn is a graduate of the University of Notre Dame with Bachelor of Science degrees in Chemical Engineering and Biochemistry. She holds an M.B.A. from Harvard Business School.
Kathryn is actively involved with a variety of portfolio companies, including
Axogen, Sierra Surgical and
WaveTec Vision Systems.
